Dermatology Medical Science Liaison - KOL Partnerships

Galderma; North Carolina, United States, Northern America, Americas; Hybrid; USD 140,000 - 190,000; Full time

Benefits offered by this job

Health insurance

401(k) plan with employer match

Generous paid time off (PTO)

Hybrid work schedules

Job summary

Galderma is seeking a Medical Science Liaison (MSL) to serve as an internal expert supporting the U.S. Nemolizumab team. The role covers NC, SC, GA, and TN, delivering scientific information to physicians, NPs, PAs, and researchers while aligning with medical affairs strategy.

The candidate will engage with KOLs, provide disease-state education, and contribute to data-generation discussions. The MSL will travel 70–80% and must have a strong clinical or research background in dermatology or

Qualifications

• Doctorate degree & 1–2 years of MSL/Medical Affairs experience preferred.
• Pharm.D., Ph.D., or MD required.
• Three or more years of clinical practice, clinical research, or medical research preferred.
• Dermatology or Immunology background preferred.

Responsibilities

• Identify and cultivate a network of external experts and KOLs in assigned geographies.
• Provide medical and scientific information to healthcare professionals in a compliant manner.
• Develop and execute KOL engagement plans and disease-area strategies.
• Generate and communicate insights to support medical affairs strategies.

Skills

Communication skills

Presentation skills

Time management

Adaptability

Teamwork

Regulatory knowledge

Problem solving

Education

Pharm.D.

Ph.D.

M.D.

Doctorate degree

Job description

Galderma is seeking a Medical Science Liaison (MSL) to serve as an internal expert supporting the U.S. Nemolizumab team. The role covers NC, SC, GA, and TN, delivering scientific information to physicians, NPs, PAs, and researchers while aligning with medical affairs strategy.

The candidate will engage with KOLs, provide disease-state education, and contribute to data-generation discussions. The MSL will travel 70–80% and must have a strong clinical or research background in dermatology or